 BidaskClub downgraded shares of Arrowhead Pharmaceuticals NASDAQ:ARWR from a buy rating to a hold rating in a research note published on Friday morning, BidAskClub reports. A number of other research firms have also weighed in on ARWR. Cantor Fitzgerald reissued a buy rating and issued a 58.00 target price down from 60.00 on shares of ... 